Stanford University
257 Campus Drive
Hagey Laboratory GK200
Stanford
California
94305-5826
United States
30 articles with Stanford University
-
New research from the Allen Institute for Immunology in Seattle has identified inflammatory proteins as a potential driver of the long COVID.
-
Bryostatin-1 increases antigen expression on the surface of cancer cells, enabling them to be seen and killed by IO agents.
-
Turn Bio’s platform is based on using mRNA technology to develop novel medicines to combat age-related diseases.
-
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
-
APOE4 is associated with an increased risk of Alzheimer’s disease. A European consortium coordinated by the University of Geneva believes they have identified at least one mechanism of action.
-
Deepcell, a biotechnology company spun out of Stanford University in 2017, focuses on quantifying and understanding morphology – part of the cell’s phenotype.
-
Researchers from UCLA believe they may have a possible new approach to treating, and potentially eradicating HIV.
-
Aditxt Signs Amendment to Extend Worldwide Licensing Agreement, Granting Exclusivity in all Fields of Use
12/29/2021
Aditxt, Inc. today announced it had signed an amendment to its February 3, 2020, Exclusive License Agreement with Stanford University, extending Aditxt’s exclusive right to license the technology deployed in AditxtScore™ and securing worldwide exclusivity in all fields of use of the licensed technology (the “Technology”).
-
Arc begins its mission with $650 million in donations from donors. This funding will sustain the scientists and their researchers over renewable eight-year terms.
-
Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection.
-
Research on the ever-evolving SARS-CoV-2 virus continues as scientists scramble to make sense of it and find cures. Here's a look.
-
Students, Venture Capitalists Launch Equity-Free Program To Support Future Biotech Leaders
9/28/2021
Nucleate, the non-profit organization seeking to support future leaders in the life sciences industry, announced its official launch and immediately opened applications to its Activator program. -
Pixium Vision expands collaboration with Stanford University on next generation Prima System implants
9/8/2021
Pixium Vision SA announces expansion of collaboration with the academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration.
-
BridgeBio Pharma Announces Collaborations with Three Academic Research Institutions
7/8/2021
BridgeBio Pharma, Inc. today announced three new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh (Pitt) to translate cutting-edge discoveries into potential therapies for patients with genetic diseases and genetically driven cancers.
-
New Life-Changing Test for Patients Diagnosed With Peanut Allergy
6/15/2021
AllerGenis announced the publication of a peer-reviewed study entitled, "Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping." Conducted by leading global experts in pediatric allergy and immunology from the Icahn School of Medicine at Mount Sinai, Stanford University and Kings College, the study found the AllerGenis peanut diagnostic blood test demonstrates accuracy significantly and statistically superior to all other established diagnostic tests.
-
Forbes highlights its "30 Under 30" list who are beginning to make their mark in the biopharma and healthcare industries.
-
Global WiDS Announces the WiDS High School Outreach Program
3/2/2020
At the Stanford Women in Data Science Conference, a new WiDS High School outreach program was announced to inspire high school students to consider careers involving data science, artificial intelligence and other related areas at their annual WiDS Conference.
-
Abeona Therapeutics Initiates Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
1/13/2020
Abeona Therapeutics Inc., a fully-integrated leader in gene and cell therapy, announced that it has received Institutional Review Board approval from Stanford University to commence the VIITAL™ study, the Company’s pivotal Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa.
-
AI System Accurately Detects Key Findings in Chest X-Rays of Pneumonia Patients Within 10 Seconds; Study Finds Promise of Faster Treatment
10/1/2019
Researchers from Intermountain Healthcare and Stanford University say 10 seconds is about how quickly a new system they studied that utilizes artificial intelligence took to accurately identify key findings in chest X-rays of patients in the emergency department suspected of having pneumonia.
-
JF Healthcare's AI Technology Is First to Beat Radiologists in Stanford Chest X-ray Diagnostic Competition
8/21/2019
JF Healthcare, a medical diagnostic start-up based in Nanchang, China, is the first organization in the world to beat Stanford University radiologists in a competition designed by the Stanford Machine Learning group to compare the capability of artificial intelligence to human experts in interpreting chest x-rays.